search
Back to results

REstrictive Versus LIberal Oxygen Strategy and Its Effect on Pulmonary Hypertension After Out-of-hospital Cardiac Arrest (RELIEPH-study) (RELIEPH)

Primary Purpose

Hypertension, Pulmonary Arterial, Out-Of-Hospital Cardiac Arrest, Intensive Care Unit

Status
Recruiting
Phase
Not Applicable
Locations
Denmark
Study Type
Interventional
Intervention
Restrictive PaO2
Low normal MAP
Liberal PaO2
High normal MAP
Sponsored by
University of Southern Denmark
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension, Pulmonary Arterial focused on measuring Out-of-hospital cardiac arrest, Resuscitation, Oxygen, Intensive Care Unit, Mechanical ventilation, Pulmonary Hypertension

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age ≥18 years
  • OHCA of presumed cardiac cause
  • Sustained ROSC
  • Unconsciousness (Glasgow coma scale <8) after sustained ROSC

Exclusion Criteria:

  • Conscious patients (obeying verbal commands)
  • Females of childbearing potential (unless a negative HCG test can rule out pregnancy within the inclusion window)
  • In-hospital cardiac arrest
  • OHCA of presumed non-cardiac cause e.g. after trauma or dissection/rupture of major artery or cardiac arrest caused by initial hypoxia (i.e. drowning, suffocation, hanging).
  • Known bleeding diathesis (medically induced coagulopathy (e.g. warfarin, NOAC, clopidogrel) does not exclude the patient)
  • Suspected or confirmed acute intracranial bleeding
  • Suspected or confirmed acute stroke
  • Unwitnessed asystole
  • Known limitations in therapy and Do Not Resuscitate-order
  • Known disease making 180 days survival unlikely
  • Known pre-arrest cerebral performance category 3 or 4
  • >4 hours (240 minutes) from ROSC to screening
  • Systolic blood pressure <80 mmHg in spite of fluid loading/vasopressor and/or inotropic medication/intra-aortic balloon pump/axial flow device
  • Temperature on admission <30°C

Sites / Locations

  • Depart med Cardiothoracic Intensive Care, Odense University HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Active Comparator

Active Comparator

Active Comparator

Active Comparator

Arm Label

Restrictive PaO2 and low normal MAP

Restrictive PaO2 and high normal MAP

Liberal PaO2 and low normal MAP

Liberal PaO2 and high normal MAP

Arm Description

Patients receiving PaO2 9-10 kPa (68-75 mmHg) and MAP 63 mmHg during targeted temperature management (36 hours) after OHCA.

Patients receiving PaO2 9-10 kPa (68-75 mmHg) and MAP 77 mmHg during targeted temperature management (36 hours) after OHCA.

Patients receiving PaO2 13-14 kPa (98-105 mmHg) and MAP 63 mmHg during targeted temperature management (36 hours) after OHCA.

Patients receiving PaO2 13-14 kPa (98-105 mmHg) and MAP 77 mmHg during targeted temperature management (36 hours) after OHCA.

Outcomes

Primary Outcome Measures

Pulmonary hypertension
Fraction of time with pulmonary hypertension (mPAP >25 mmHg) out of total time with mechanical ventilation.

Secondary Outcome Measures

Length of ICU stay.
Length of ICU stay among survivors.
Lactate clearance.
>30% reduction in lactate level.
Right ventricular failure.
Cardiac index <2 and central venous pressure >18 mmHg.
Mortality.
Dead or alive.
Plasma brain natriuretic peptide.
Plasma brain natriuretic peptide level.

Full Information

First Posted
August 11, 2021
Last Updated
May 31, 2022
Sponsor
University of Southern Denmark
search

1. Study Identification

Unique Protocol Identification Number
NCT05029167
Brief Title
REstrictive Versus LIberal Oxygen Strategy and Its Effect on Pulmonary Hypertension After Out-of-hospital Cardiac Arrest (RELIEPH-study)
Acronym
RELIEPH
Official Title
REstrictive Versus LIberal Oxygen Strategy and Its Effect on Pulmonary Hypertension After Out-of-hospital Cardiac Arrest (RELIEPH-study): a Substudy Protocol for a Randomised Clinical Trial
Study Type
Interventional

2. Study Status

Record Verification Date
May 2022
Overall Recruitment Status
Recruiting
Study Start Date
September 11, 2017 (Actual)
Primary Completion Date
September 2023 (Anticipated)
Study Completion Date
December 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Southern Denmark

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Background: For patients with out-of-hospital cardiac arrest (OHCA) at the intensive care unit (ICU), oxygen therapy plays an important role in post resuscitation care. During hospitalisation, a lot of these patients occur with pulmonary arterial hypertension (PAH). Currently a wide oxygen target is recommended but no evidence regarding optimal treatment targets to minimise the prevalence of PAH exists. Methods: The RELIEPH trial is a substudy within the BOX (Blood pressure and OXygenation targets in post resuscitation care) trial. It is a single-center, parallel-group randomised controlled clinical trial. 300 patients with OHCA hospitalised at the ICU are allocated to one of the two oxygenation interventions, either a restrictive- (9-10 kPa) or liberal (13-14 kPa) oxygen target both within the recommended range. The primary outcome is the fraction of time with pulmonary hypertension (mPAP >25 mmHg) out of total time with mechanical ventilation. Secondary outcomes are: length of ICU stay among survivors, lactate clearance, right ventricular failure, 30 days mortality and plasma brain natriuretic peptide (BNP) level 48 hours from randomisation. Discussion: This study hypothesises that a liberal target of oxygen reduces the time with PAH during mechanical ventilation compared to a restrictive oxygen target in patients with OHCA at the ICU. When completed, this study hopes to provide new knowledge regarding which oxygen target is beneficial for this group of patients.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension, Pulmonary Arterial, Out-Of-Hospital Cardiac Arrest, Intensive Care Unit, Oxygen Therapy, Mechanical Ventilation, Resuscitation
Keywords
Out-of-hospital cardiac arrest, Resuscitation, Oxygen, Intensive Care Unit, Mechanical ventilation, Pulmonary Hypertension

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
The RELIEPH trial is a substudy of the BOX trial, which is a multicenter, randomised clinical trial with a 2x2 factorial design. Patients are allocated 1:1:1:1 to two interventions, respectively high- or low mean arterial pressures (double blinded) and restrictive- or liberal oxygenation (open label). The RELIEPH trial focuses on the oxygen intervention and only has access to data from one trial site. This makes the RELIEPH trial a single-center, parallel-group randomised controlled trial with patients allocated 1:1 to the oxygen target interventions.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
300 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Restrictive PaO2 and low normal MAP
Arm Type
Active Comparator
Arm Description
Patients receiving PaO2 9-10 kPa (68-75 mmHg) and MAP 63 mmHg during targeted temperature management (36 hours) after OHCA.
Arm Title
Restrictive PaO2 and high normal MAP
Arm Type
Active Comparator
Arm Description
Patients receiving PaO2 9-10 kPa (68-75 mmHg) and MAP 77 mmHg during targeted temperature management (36 hours) after OHCA.
Arm Title
Liberal PaO2 and low normal MAP
Arm Type
Active Comparator
Arm Description
Patients receiving PaO2 13-14 kPa (98-105 mmHg) and MAP 63 mmHg during targeted temperature management (36 hours) after OHCA.
Arm Title
Liberal PaO2 and high normal MAP
Arm Type
Active Comparator
Arm Description
Patients receiving PaO2 13-14 kPa (98-105 mmHg) and MAP 77 mmHg during targeted temperature management (36 hours) after OHCA.
Intervention Type
Other
Intervention Name(s)
Restrictive PaO2
Other Intervention Name(s)
PaO2 target at 9-10 kPa.
Intervention Description
Patients are randomized to a PaO2 target of 9-10 kPa (open-label).
Intervention Type
Other
Intervention Name(s)
Low normal MAP
Other Intervention Name(s)
Mean arterial blood pressure at 63 mmHg.
Intervention Description
The patients are randomized to receive a Phillips M1006B blood pressure measuring module, offset by +10 %. All patients will target a MAP of 70, but due to the offset module, the patients will target an actual blood pressure of 63 mmHg.
Intervention Type
Other
Intervention Name(s)
Liberal PaO2
Other Intervention Name(s)
PaO2 target at 13-14 kPa.
Intervention Description
Patients are randomized to a PaO2 target of 13-14 kPa (open-label).
Intervention Type
Other
Intervention Name(s)
High normal MAP
Other Intervention Name(s)
Mean arterial blood pressure at 77 mmHg.
Intervention Description
The patients are randomized to receive a Phillips M1006B blood pressure measuring module, offset by -10 %. All patients will target a MAP of 70, but due to the offset module, the patients will target an actual blood pressure of 77mmHg.
Primary Outcome Measure Information:
Title
Pulmonary hypertension
Description
Fraction of time with pulmonary hypertension (mPAP >25 mmHg) out of total time with mechanical ventilation.
Time Frame
Up to 30 days.
Secondary Outcome Measure Information:
Title
Length of ICU stay.
Description
Length of ICU stay among survivors.
Time Frame
Up to 8 weeks.
Title
Lactate clearance.
Description
>30% reduction in lactate level.
Time Frame
24 hours.
Title
Right ventricular failure.
Description
Cardiac index <2 and central venous pressure >18 mmHg.
Time Frame
Up to 8 weeks.
Title
Mortality.
Description
Dead or alive.
Time Frame
30 days after ROSC.
Title
Plasma brain natriuretic peptide.
Description
Plasma brain natriuretic peptide level.
Time Frame
48 hours from randomisation.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age ≥18 years OHCA of presumed cardiac cause Sustained ROSC Unconsciousness (Glasgow coma scale <8) after sustained ROSC Exclusion Criteria: Conscious patients (obeying verbal commands) Females of childbearing potential (unless a negative HCG test can rule out pregnancy within the inclusion window) In-hospital cardiac arrest OHCA of presumed non-cardiac cause e.g. after trauma or dissection/rupture of major artery or cardiac arrest caused by initial hypoxia (i.e. drowning, suffocation, hanging). Known bleeding diathesis (medically induced coagulopathy (e.g. warfarin, NOAC, clopidogrel) does not exclude the patient) Suspected or confirmed acute intracranial bleeding Suspected or confirmed acute stroke Unwitnessed asystole Known limitations in therapy and Do Not Resuscitate-order Known disease making 180 days survival unlikely Known pre-arrest cerebral performance category 3 or 4 >4 hours (240 minutes) from ROSC to screening Systolic blood pressure <80 mmHg in spite of fluid loading/vasopressor and/or inotropic medication/intra-aortic balloon pump/axial flow device Temperature on admission <30°C
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Mie Mørkøre, MS
Phone
+45 28555083
Email
mie.moerk@outlook.dk
First Name & Middle Initial & Last Name or Official Title & Degree
Rikke Ingerslev Stage, MS
Phone
+45 28569220
Email
rikke.i.stage@gmail.com
Facility Information:
Facility Name
Depart med Cardiothoracic Intensive Care, Odense University Hospital
City
Odense
State/Province
Syddanmark
ZIP/Postal Code
5000
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Henrik Schmidt, DMSci
Email
Henrik.Schmidt@rsyd.dk
First Name & Middle Initial & Last Name & Degree
Henrik Schmidt, DMSci
First Name & Middle Initial & Last Name & Degree
Simon Mølstrøm, MD

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Data obtained through this study may be provided to qualified researchers with academic interest in post-resuscitation care. Data or samples shared will be coded, with no protected health information included. Approval of the request and execution of all applicable agreements (i.e. a material transfer agreement) are prerequisites to the sharing of data with the requesting party.
IPD Sharing Time Frame
Data requests can be submitted starting 9 months after article publication and the data will be made accessible for up to 24 months. Extensions will be considered on a case-by-case basis.
IPD Sharing Access Criteria
Access to trial IPD can be requested by qualified researchers engaging in independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan and execution of a Data Sharing Agreement.
Citations:
PubMed Identifier
24797375
Citation
Zhang Z, Xu X. Lactate clearance is a useful biomarker for the prediction of all-cause mortality in critically ill patients: a systematic review and meta-analysis*. Crit Care Med. 2014 Sep;42(9):2118-25. doi: 10.1097/CCM.0000000000000405.
Results Reference
background
PubMed Identifier
25261605
Citation
Young P, Bailey M, Bellomo R, Bernard S, Dicker B, Freebairn R, Henderson S, Mackle D, McArthur C, McGuinness S, Smith T, Swain A, Weatherall M, Beasley R. HyperOxic Therapy OR NormOxic Therapy after out-of-hospital cardiac arrest (HOT OR NOT): a randomised controlled feasibility trial. Resuscitation. 2014 Dec;85(12):1686-91. doi: 10.1016/j.resuscitation.2014.09.011. Epub 2014 Sep 28.
Results Reference
background
PubMed Identifier
32832091
Citation
Yamamoto R, Yoshizawa J. Oxygen administration in patients recovering from cardiac arrest: a narrative review. J Intensive Care. 2020 Aug 12;8:60. doi: 10.1186/s40560-020-00477-w. eCollection 2020.
Results Reference
background
PubMed Identifier
24355639
Citation
Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, Gomez Sanchez MA, Krishna Kumar R, Landzberg M, Machado RF, Olschewski H, Robbins IM, Souza R. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D34-41. doi: 10.1016/j.jacc.2013.10.029. Erratum In: J Am Coll Cardiol. 2014 Feb 25;63(7):746. J Am Coll Cardiol. 2014 Feb 25;63(7):746.
Results Reference
background
PubMed Identifier
33471452
Citation
Schjorring OL, Klitgaard TL, Perner A, Wetterslev J, Lange T, Siegemund M, Backlund M, Keus F, Laake JH, Morgan M, Thormar KM, Rosborg SA, Bisgaard J, Erntgaard AES, Lynnerup AH, Pedersen RL, Crescioli E, Gielstrup TC, Behzadi MT, Poulsen LM, Estrup S, Laigaard JP, Andersen C, Mortensen CB, Brand BA, White J, Jarnvig IL, Moller MH, Quist L, Bestle MH, Schonemann-Lund M, Kamper MK, Hindborg M, Hollinger A, Gebhard CE, Zellweger N, Meyhoff CS, Hjort M, Bech LK, Grofte T, Bundgaard H, Ostergaard LHM, Thyo MA, Hildebrandt T, Uslu B, Solling CG, Moller-Nielsen N, Brochner AC, Borup M, Okkonen M, Dieperink W, Pedersen UG, Andreasen AS, Buus L, Aslam TN, Winding RR, Schefold JC, Thorup SB, Iversen SA, Engstrom J, Kjaer MN, Rasmussen BS; HOT-ICU Investigators. Lower or Higher Oxygenation Targets for Acute Hypoxemic Respiratory Failure. N Engl J Med. 2021 Apr 8;384(14):1301-1311. doi: 10.1056/NEJMoa2032510. Epub 2021 Jan 20.
Results Reference
background
PubMed Identifier
26334785
Citation
Panwar R, Hardie M, Bellomo R, Barrot L, Eastwood GM, Young PJ, Capellier G, Harrigan PW, Bailey M; CLOSE Study Investigators; ANZICS Clinical Trials Group. Conservative versus Liberal Oxygenation Targets for Mechanically Ventilated Patients. A Pilot Multicenter Randomized Controlled Trial. Am J Respir Crit Care Med. 2016 Jan 1;193(1):43-51. doi: 10.1164/rccm.201505-1019OC.
Results Reference
background
PubMed Identifier
26464394
Citation
Nolan JP, Soar J, Cariou A, Cronberg T, Moulaert VR, Deakin CD, Bottiger BW, Friberg H, Sunde K, Sandroni C; European Resuscitation Council; European Society of Intensive Care Medicine. European Resuscitation Council and European Society of Intensive Care Medicine 2015 guidelines for post-resuscitation care. Intensive Care Med. 2015 Dec;41(12):2039-56. doi: 10.1007/s00134-015-4051-3. Erratum In: Intensive Care Med. 2016 Mar;42(3):488-9.
Results Reference
background
PubMed Identifier
6017244
Citation
Nash G, Blennerhassett JB, Pontoppidan H. Pulmonary lesions associated with oxygen therapy and artificial ventilation. N Engl J Med. 1967 Feb 16;276(7):368-74. doi: 10.1056/NEJM196702162760702. No abstract available.
Results Reference
background
PubMed Identifier
15591309
Citation
Moudgil R, Michelakis ED, Archer SL. Hypoxic pulmonary vasoconstriction. J Appl Physiol (1985). 2005 Jan;98(1):390-403. doi: 10.1152/japplphysiol.00733.2004.
Results Reference
background
PubMed Identifier
25953750
Citation
McLaughlin VV, Shah SJ, Souza R, Humbert M. Management of pulmonary arterial hypertension. J Am Coll Cardiol. 2015 May 12;65(18):1976-97. doi: 10.1016/j.jacc.2015.03.540.
Results Reference
background
PubMed Identifier
16356246
Citation
Luecke T, Pelosi P. Clinical review: Positive end-expiratory pressure and cardiac output. Crit Care. 2005;9(6):607-21. doi: 10.1186/cc3877. Epub 2005 Oct 18.
Results Reference
background
PubMed Identifier
31021845
Citation
Kirkegaard H, Taccone FS, Skrifvars M, Soreide E. Postresuscitation Care after Out-of-hospital Cardiac Arrest: Clinical Update and Focus on Targeted Temperature Management. Anesthesiology. 2019 Jul;131(1):186-208. doi: 10.1097/ALN.0000000000002700.
Results Reference
background
PubMed Identifier
23089677
Citation
Huynh TN, Weigt SS, Sugar CA, Shapiro S, Kleerup EC. Prognostic factors and outcomes of patients with pulmonary hypertension admitted to the intensive care unit. J Crit Care. 2012 Dec;27(6):739.e7-13. doi: 10.1016/j.jcrc.2012.08.006. Epub 2012 Oct 22.
Results Reference
background
PubMed Identifier
27321577
Citation
Grasner JT, Lefering R, Koster RW, Masterson S, Bottiger BW, Herlitz J, Wnent J, Tjelmeland IB, Ortiz FR, Maurer H, Baubin M, Mols P, Hadzibegovic I, Ioannides M, Skulec R, Wissenberg M, Salo A, Hubert H, Nikolaou NI, Loczi G, Svavarsdottir H, Semeraro F, Wright PJ, Clarens C, Pijls R, Cebula G, Correia VG, Cimpoesu D, Raffay V, Trenkler S, Markota A, Stromsoe A, Burkart R, Perkins GD, Bossaert LL; EuReCa ONE Collaborators. EuReCa ONE-27 Nations, ONE Europe, ONE Registry: A prospective one month analysis of out-of-hospital cardiac arrest outcomes in 27 countries in Europe. Resuscitation. 2016 Aug;105:188-95. doi: 10.1016/j.resuscitation.2016.06.004. Epub 2016 Jun 16. Erratum In: Resuscitation. 2016 Dec;109 :145-146.
Results Reference
background
PubMed Identifier
11905405
Citation
Gomersall CD, Joynt GM, Freebairn RC, Lai CK, Oh TE. Oxygen therapy for hypercapnic patients with chronic obstructive pulmonary disease and acute respiratory failure: a randomized, controlled pilot study. Crit Care Med. 2002 Jan;30(1):113-6. doi: 10.1097/00003246-200201000-00018.
Results Reference
background
PubMed Identifier
27706466
Citation
Girardis M, Busani S, Damiani E, Donati A, Rinaldi L, Marudi A, Morelli A, Antonelli M, Singer M. Effect of Conservative vs Conventional Oxygen Therapy on Mortality Among Patients in an Intensive Care Unit: The Oxygen-ICU Randomized Clinical Trial. JAMA. 2016 Oct 18;316(15):1583-1589. doi: 10.1001/jama.2016.11993.
Results Reference
background
PubMed Identifier
19077208
Citation
de Jonge E, Peelen L, Keijzers PJ, Joore H, de Lange D, van der Voort PH, Bosman RJ, de Waal RA, Wesselink R, de Keizer NF. Association between administered oxygen, arterial partial oxygen pressure and mortality in mechanically ventilated intensive care unit patients. Crit Care. 2008;12(6):R156. doi: 10.1186/cc7150. Epub 2008 Dec 10.
Results Reference
background
PubMed Identifier
28219612
Citation
Asfar P, Schortgen F, Boisrame-Helms J, Charpentier J, Guerot E, Megarbane B, Grimaldi D, Grelon F, Anguel N, Lasocki S, Henry-Lagarrigue M, Gonzalez F, Legay F, Guitton C, Schenck M, Doise JM, Devaquet J, Van Der Linden T, Chatellier D, Rigaud JP, Dellamonica J, Tamion F, Meziani F, Mercat A, Dreyfuss D, Seegers V, Radermacher P; HYPER2S Investigators; REVA research network. Hyperoxia and hypertonic saline in patients with septic shock (HYPERS2S): a two-by-two factorial, multicentre, randomised, clinical trial. Lancet Respir Med. 2017 Mar;5(3):180-190. doi: 10.1016/S2213-2600(17)30046-2. Epub 2017 Feb 15. Erratum In: Lancet Respir Med. 2017 Aug;5(8):e28.
Results Reference
background
PubMed Identifier
24141714
Citation
World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013 Nov 27;310(20):2191-4. doi: 10.1001/jama.2013.281053. No abstract available.
Results Reference
background
Links:
URL
http://clinicaltrials.gov/show/NCT03141099
Description
Blood Pressure and OXygenation Targets After OHCA

Learn more about this trial

REstrictive Versus LIberal Oxygen Strategy and Its Effect on Pulmonary Hypertension After Out-of-hospital Cardiac Arrest (RELIEPH-study)

We'll reach out to this number within 24 hrs